ERBB2 and breast cancer: Furthermore, the expression levels of miRNA-221 and -222 were also significantly elevated in HER2/neu-positive primary human breast cancer tissues, which are known to be resistant to endocrine therapy, compared with HER2/neu-negative tissue samples.